Mr. Garen Sarafian reports

BAUSCH HEALTH CEO THOMAS J. APPIO JOINS BAUSCH + LOMB BOARD

Bausch Health Companies Inc.'s chief executive officer, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb Corp., a subsidiary of Bausch Health, effective Aug. 5, 2026.

"Bausch + Lomb is an important asset of Bausch Health, and I look forward to working with the board to support its strategy and help drive long-term value for shareholders," said Mr. Appio.

In addition, Robert J. Chersi, Laurence E. Paul, MD, and Barbara J. Trebbi have joined the Bausch + Lomb board of directors. The new directors replace Steven Collis, Karen Ling, Thomas Ross and Andrew von Eschenbach, MD, each of whom has tendered his or her resignation to facilitate the new appointments. None of the resignations were the result of any disagreement with Bausch + Lomb.

Bausch Health is Bausch + Lomb's largest shareholder, holding approximately 87 per cent of its outstanding common shares indirectly through its wholly owned subsidiaries. The company continues to support Bausch + Lomb's strategy and long-term growth objectives.

These board changes were requested by Bausch Health and are consistent with its existing ownership position in Bausch + Lomb.

About Bausch Health Companies Inc.

Bausch Health is a global, diversified pharmaceutical company enriching lives through its relentless drive to deliver better health care outcomes. It develops, manufactures and markets a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb. Its ambition is to be a globally integrated health care company, trusted and valued by patients, HCPs, employees and investors.

We seek Safe Harbor.